Archive for March, 2017


March 4, 2017


Phase I/II data presented at 2017 late-breaking research at American Academy of Dermatology

Short Hills, NJ, March 4, 2017– Tamir Biotechnology, a leading developer of antiviral therapies, presented data demonstrating the safety and efficacy of topical ranpirnase in the treatment of HPV associated genital warts during the 2017 American Academy of Dermatology late-breaking research session. The company’s leading asset, topical ranpirnase, was evaluated in a formal phase I/II, double blinded investigation in seventy-five (75) immunocompetent subjects with genital warts. Patients received either topical ranpirnase or vehicle (control), with twice a day application to the affected area for a period of eight (8) weeks. The dose of ranpirnase was 1mg/week.

(more…)

Continue reading
Back to top